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Background: Tenofovir disoproxil fumarate (TDF) is a nucleotide rever-
se transcriptase inhibitor (NRTI). TDF is generally well tolerated in the 
body. It is eliminated by glomerular filtration and active renal tubular 
secretion. So, it can be responsible for renal toxicity. The aim of our 
study is to assess the prevalence of TDF nephrotoxicity and its factors 
risk in people living with HIV (PLHIV) treated in the Infectious Diseases 
Department at the University Hospital of Monastir, Tunisia.
Methods: An observational cross-sectional single-centre prospective 
study included 62 cases of PLVIH taking antiretroviral therapy (ART) 
containing TDF was conducted between 1 August 1st 2016 and 31 
December 2016 at Fattouma Bourguiba University Hospital of Mo-
nastir, in Tunisia. During this period, patients were screened for renal 
dysfunction to detect renal toxicity, Tubular dysfunction or Fanconi 
syndrome.
Results: 62 patients were included with male/female sex-ratio 1.58 
(38 male). The age was (mean ± SD) 39 years ± 8.5 years. Half of the 
patients were treated with TDF as first-line therapy. The average dura-
tion of TDF was 25 months, the duration was greater than 12 months 
in 40 (65%) patients. There was a decrease in creatinine clearance in 
21 (33.8%) patients, the average of the decrease was (mean ± SD) 
128.6 ± 35.8 ml/min. Proximal tubulopathy was noted in 1 patient 
(1.6%) and no patient had Fanconi syndrome.
No risk factors for renal impairment under TDF were found. This 
finding could be explained by the small sample size
Conclusion: TDF-related renal toxicity is often asymptomatic, it re-
quires early detection. In our patients, Tubular dysfunction (TD) is 
rare, but creatinine clearance decrease is frequent and may inform of 
possible TD in these patient. In order to reduce TDF toxicity, a new 
pro-drug, tenofovir alafenamide (TAF), is now available.
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Introduction
The introduction of highly active antiretroviral thera-
py (HAART) has significantly reduced morbidity and 
mortality for PLHIV [1].
Tenofovir disoproxil fumarate (TDF) is a nucleotide 
reverse transcriptase inhibitor (NRTI). It is used in the 
first line-preferred regimen, currently recommended 
by WHO [2]. 
According to Tunisian recommendations, first-line 
antiretroviral therapy (ART) may include two reverse 
transcriptase inhibitors (NRTIs) associated with a ri-
tonavir boosted protease inhibitor (PI/r) or two NRTI 
associated with an NNRTI. So, the combination of 
TDF with Emtricitabine (FTC) and efavirenz (EFV) is 
mostly used. Furthermore, TDF is part of the first-
line ART combination in more than 144 countries 
particularly in middle and low incomes countries.
In addition to its effectiveness, TDF is characte-
rized by its good tolerance. It is eliminated by the 
combination of glomerular filtration and active renal 
tubular secretion. Thus, it can lead to renal toxicity 
on the long or short terms.
 This nephrotoxicity is estimated at less than 5% 
in European studies. It is commonly asymptomatic 
and requires early detection and can be reversible 
after stopping TDF [3].
So, the main objective of our study is to assess 
the prevalence of TDF nephrotoxicity and risk fac-
tors in PLHIV followed at Monastir University Hos-
pital in Infectious Disease Department. 
Methods 
This was an observational cross-sectional single-
centre prospective study involving 62 HIV-infected 
patients taking ART containing TDF. This study was 
conducted between 1 August 2016 and 31 Decem-
ber 2016.
During this period, patients were screened for 
renal dysfunction by urine dipsticks, serum creati-
nine, calcium level, glucose level, phosphate level 
and blood gases. Abnormalities were verified by a 
second sample. Demographic, medical and labora-
tory data was collected from case records.
Creatinine clearance (CrCL) was calculated using 
the Cockroft-Gault equation, based on local prac-
tice patterns.
Tubular dysfunction (TD) was defined as having 
two or more characteristic features: decrease of 
CrCL, positive glycosuria, proteinuria, urine phospha-
te level >42 mmol/l, tubular acidosis (PH<5) and 
decrease of serum phosphate level <0.3 mmol/L.
Fanconi syndrome was due to alteration in the 
resorption, which are specific for each of the subs-
tances reabsorbed in the proximal tubule. It was 
detected by developing glucosuria, phosphaturia, 
aminoaciduria, bicarbonaturia, and proteinuria, as-
sociated with urinary decrease in Na+/K+, ATPase 
and ATP levels. [4]
To detect any abnormalities, we performed a des-
criptive and analytic study using SPSS 20.0. 
Results 
Sixty two patients were included, the male/female 
ratio was 1.58. The mean age was 39 years ± 8.5 
years. Fourty eight patients (77.4%) were aged bet-
ween 30 and 50 years and 5 patients (8.1%) were 
50 years and older.
All the patients were treated with ART containing 
TDF. This last was prescribed as second line regimen 
on half of cases. This switch was due to failure in 10 
cases (32.2%) and to side effects in 5 cases (16.1%). 
Only one patient was diabetic and no nephrotoxic 
medication was used by patients. TDF was used for 
a median duration of 19 months with a range of 
10.5 -28 months. The characteristics of the popula-
tion are shown in Table 1.
The mean of Cr Cl was 128.6 ± 35.8 ml/min after 
mean duration of TDF use of 25 months. Fifty eight 
(93.5%) had Cr Cl more than 90 ml/min. A decrease 
of Cr Cl was noted on 21 patients (33.8%) with a 
mean decrease of 19.8 ± 17.8ml/min. Proteinuria 
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was common, found in 10 cases (16.1%) of the enti-
re cohort. Two patients (3.2%) had urine phosphate 
more than 42 mmol/L. All others biological charac-
teristics were normal (Table 2).
Tubular dysfunction was detected in one patient 
(1.6%). A 38-year-old female without medical his-
tory. She had been treated with TDF for 8 months. 
She hadn’t any nephrotoxic medication. Her kid-
ney ultrasound was normal and her CD4 count 
is 489 cells/mm3. No cases of Fanconi syndrome 
were detected. All the abnormalities were shown 
in Table 2.
Discussion 
TDF, the first approved oral prodrug of tenofovir, has 
been used in combination ART for the treatment of 
HIV-1 infection since 2001 [5]. It is generally well 
tolerated. However, TDF may cause an acute renal 
failure. In the literature, TDF toxicity accounted for 
2.5% to 11% of cases [6]. The main TDF-related to-
xicity is a proximal tubular dysfunction, while altered 
GFR and progressive advanced renal disease. This 
toxicity was reported with a discordant outcomes. 
The mechanism of TDF kidney damage is unclear. 
Two assumptions were made, mitochondrial toxicity 
and direct interference with epithelial cells of the 
renal tubular function.
This nephrotoxicity is proximal tubulopathy with 
proteinuria, hypophosphatemia and Fanconi syndro-
me (tubular acidosis) occurred rarely.
Renal toxicity may be a decrease of creatinine 
clearance, a tubular defect or Fanconi syndrome. 
All these manifestations are related to a tubular 
cells dysfunction. TDF is toxic for mithochondrial 
function. So, cells don’t produce energy and can’t 
provide its usual function. Thus, resorption and se-
cretion are altered. This hypothesis was confirmed 
by detection of ultrastructral anomalies for PLHIV 
treated with TDF. Its frequency increase with TDF 
use. It is estimate for about 1.5/1000 patients-year 
[6].
Many chemical abnormalities may detect renal 
toxicity. Such as decrease of Creatinine clearance, 
positive glycosuria, proteinuria, urine phosphate le-
vel, tubular acidosis (PH<5) and decrease of serum 
phosphate level [7].
Decrease of creatinine clearance after TDF using 
is frequently reported in literature and can achieve 
13.3 mL/min. Creatinine clearance less than 70 mL/
min is noted in 5/1000 patients-years. In our study 
decrease of creatinine clearance was noted in 21 
patients (33.8%). The mean value was 19.8 ml/
min ± 17.8 mL/min. This renal toxicity is reversible 
after stopping TDF [6]. In our study, no patients 
stopped TDF.
Table 1.  Epidemiological, clinical and biological cha-




Age (years) 39 8.5
BMI (Kg) 70 13.9
Initial creatinine (µmol/L) 115.33 35.9
Initial viral load 
(copies/mL)
1544628.167 7250708.739
Initial CD4 count 
(cells/mm3)
291 296
Undetectable viral load 
due to TDF (patients)
55







(ml/min) 128.64 35.88 4
Decrease of creatinine 
clearance (ml/min)
19.8 17.8 21
Phosphate Serum level 
(mmol/L)
0.93 0.17 0
Phosphate urine level 
(mmol/L)
18.25 9.37 2
Urine pH 6.45 0.31 0
Urine glucose level - - 0
Proteinuria - - 10
The univariate analysis didn’t show any risk factors of tubular defect.
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Also, TDF can be responsible for tubular dys-
function. So, there is decrease of serum phospha-
te level, positive glycosuria, proteinuria and urine 
phosphate level. These abnormalities may exist with 
normal creatinine [6].
This tubular dysfunction is associated with some 
histological features. We obviously note acute pro-
ximal tubular necrosis. But the main characteristic 
feature is to have broad eosinophilic inclusion [8]. 
An increase in tubular dysfunction in patients on 
TDF-based ART is noted in some European and Afri-
can studies. It frequency is between 7 to 22% [9]. 
In our study, we identified one patient (1.6%) with 
tubular dysfunction. TDF was identified responsible 
for this tubular dysfunction because the patient 
doesn’t take any other treatment and doesn’t have 
any other diseases which explain renal defect.
Fanconi syndrome is rarely reported in literature 
[3]. Its frequency is less than 5%. Its diagnosis can 
be established after a polyuria-polydipsia syndrome, 
asthenia, arthralgia and myalgia. Occasionally Fan-
coni syndrome may can be diagnosed clinically, TDF 
related Fanconi syndrome can be diagnosed after a 
mean duration of 10 months (1 to 24 months) of 
using TDF .This syndrome is reversible after stopping 
the drug [4]. However, in some severe cases, we 
must use hemodialysis or renal transplantation. No 
case of Fanconi syndrome was noted in our study.
Many risk factors are detected in studies. So renal 
failure before treatment, low body mass index, dia-
betes and CD4 count less than 20 cells/mm3 were 
identified to be associated to renal toxicity related 
to TDF [10, 11].
Also, protease inhibitors or didanosine use with 
TDF may increase renal toxicity. In these cases Fan-
coni syndrome was noted more than 40% [12].
But, the main risk factor for renal toxicity is TDF 
duration of use, toxicity is more frequent if TDF du-
ration is more than 12 months [6].
In our study, we didn’t note any risk factors. These 
findings were explained by small sample of patients. 
Weaknesses of this study include TDF duration was 
relatively short, especially 40 patients were treated 
with TDF for 12 months. Also, the relatively small 
sample of patients who were tested for features of 
tubular dysfunction limited the power of the analy-
ses to demonstrate correlations of postulated risk 
factors for TD. Finally, our population is too young 
which explains absence of a previous medical his-
tory and the use of toxic drugs. Recently, Tenofovir 
alafenamide (TAF) was found safer with similar effi-
ciency to TDF [13]. This drug can be used in patient 
with renal failure and creatinine clearance less than 
60 ml/min [14].
Conclusions
In summary this study showed that renal toxicity is 
common amongst Tunisian PLHIV taking ART. TDF 
was associated with toxicity. Monitoring of renal 
function (twice per year) and excluding high risk 
patients for renal injury is recommended.
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